CD276 and cancer: The combined hazard ratio (HR) for these 11 cancer types evaluating CD276 expression is 1.22 (95% CI: 1.06–1.42, P < 0.001) and together with the mTORC1 score is 1.23 (95% CI: 0.99–1.53, P = 0.058), suggesting that the combined CD276 expression and mTORC1 score is an indicator of poor prognosis (Fig. 1d–f).